IDH1(R132) Peptide Vaccine Yields 66% Eight-Year Survival in Phase 1 Glioma Cohort
Phase 1 data from 33 patients demonstrate encouraging long-term survival with an IDH1 neoepitope vaccine, mechanistically tied to intratumoral T-cell infiltration. Small size and lack of randomization limit causal inference. Larger controlled studies are needed to establish efficacy.
The findings reinforce that clonal, early driver mutations can serve as stable neoantigens when presented in an immunogenic formulation. Remaining questions include durability beyond eight years, optimal boosting schedule, and activity in lower-grade IDH1-mutant tumors. A randomized phase 2/3 trial with centralized immune monitoring is required to confirm clinical benefit and identify predictive biomarkers.
NOA16 investigators: randomized phase 2 will report median PFS exceeding 30 months in vaccine arm versus control by December 2029.
Sources (2)
- [1]Primary Source(https://www.nature.com/articles/s43018-026-01199-y)
- [2]Supporting Source(https://www.nejm.org/doi/10.1056/NEJMoa2104476)